2016
DOI: 10.1177/2040622316641352
|View full text |Cite
|
Sign up to set email alerts
|

Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications

Abstract: Treatment for cystic fibrosis (CF) has conventionally targeted downstream consequences of the defect such as mucus plugging and infection. More recently, significant advances have been made in treating the root cause of the disease, namely a defective CF transmembrane conductance regulator (CFTR) gene. This review summarizes current pulmonary treatment options and highlights advances in research and development of new therapies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
35
0
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
5
4
1

Relationship

0
10

Authors

Journals

citations
Cited by 46 publications
(36 citation statements)
references
References 97 publications
0
35
0
1
Order By: Relevance
“…Second, practical applications based on purine metabolism did not yield positive results. For instance, the P2Y 2 receptor agonist denufosol failed to show replicable results in phase III clinical trials [52], and to the best of our knowledge, there are, at the moment, no chemical compounds in clinical trials that target purine metabolism. Third, compounds associated with SPLUNC1, while in the early stages of clinical tests, have been producing positive results [27,53,54]; correspondingly, we focused on the relationships between ENaC, ASL, SPLUNC1 and PI(4,5)P 2 .…”
Section: Discussionmentioning
confidence: 99%
“…Second, practical applications based on purine metabolism did not yield positive results. For instance, the P2Y 2 receptor agonist denufosol failed to show replicable results in phase III clinical trials [52], and to the best of our knowledge, there are, at the moment, no chemical compounds in clinical trials that target purine metabolism. Third, compounds associated with SPLUNC1, while in the early stages of clinical tests, have been producing positive results [27,53,54]; correspondingly, we focused on the relationships between ENaC, ASL, SPLUNC1 and PI(4,5)P 2 .…”
Section: Discussionmentioning
confidence: 99%
“…Beside amyloid and tau pathology, alternative theories have been proposed for the pathogenesis of AD, such as inflammation, oxidative damage, iron deregulation, and cholesterol metabolism, etc. [ 31 , 32 ].…”
Section: Ad Pathophysiology and Treatment Statusmentioning
confidence: 99%
“… 14 , 20 Standard strategies used in CF treatment, the fluidization of the sputum by a recombinant human deoxyribonuclease (rhDNase) and using antibiotics in high doses in a systemic and aerosolized form can at least partially overcome the inhibiting influence of a polyanionic network. 21 Although the utility of rhDNase significantly improves lung function, not all patients with CF benefit from this treatment. 22 Therefore, there is a continuous need for new effective therapies.…”
Section: Discussionmentioning
confidence: 99%